Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease.

Anna Daunt Pablo N Perez-Guzman Felicity Liew Katharina Hauck Ceire E Costelloe Mark R Thursz Graham Cooke Shevanthi Nayagam

J Infect

MRC Centre for Global Infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, United Kingdom; Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, United Kingdom. Electronic address:

Published: October 2020

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306204	PMC
http://dx.doi.org/10.1016/j.jinf.2020.06.049	DOI Listing

Publication Analysis

Top Keywords

validity early

early access

access medicines

medicines scheme

scheme criteria

criteria remdesivir

remdesivir patients

patients covid-19

covid-19 disease

validity

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!